The agreement signed by two parties on June 30 is aimed at supporting “the development of DARE-LARC1, our investigational user-controlled, long-acting reversible contraceptive,” Daré Bioscience said in a regulatory filing yesterday.
- HQ: San Diego, CA
- http://www.darebioscience.com
- The grant will enable the company to advance DARE-LARC1 from pre-clinical studies to clinical studies over a period of more than five years from June 30, 2021, to November 1, 2026.
- Daré Bioscience is entitled to an initial payment of $11.5M in July, followed by additional payments subject to the achievement of milestones related to the DARE-LARC1 during the grant period.
- Last month, the company shares rose on the announcement of positive topline results from its early-stage trial of DARE-HRT1.
No comments:
Post a Comment